The p300/CBP inhibitor company
50+
Epigenetic-related targets
investigated over time by the CellCentric team
1
Drug prioritised, advanced
Inobrodib in the clinic, to treat specific cancers
p300/CBP are twin (paralogue) acetyl transferases and gene activating proteins that are known to play an important role in the progression of certain cancers.
Inobrodib is a novel drug which inhibits p300/CBP by binding to the twin proteins’ conserved bromodomain. This impacts the growth of specific types of cancer.
CellCentric’s pioneering drug is in clinical trials to evaluate its effectiveness to treat late-stage prostate cancer, haematological malignancies (blood cancers) and tumours with certain molecular drivers (over-expressing AR or MYC; or with a p300 or CBP mutation). These represent major clinical unmet needs, delivering a new therapy for patients that otherwise have few alternatives.
CellCentric’s clinical & scientific leadership will be as ASCO 2022. We continue to advance our pioneering p300/CBP inhibitor to treat specific cancers. #ASCO22 pic.twitter.com/SciCvWzilS
It’s international clinical trials day. Inobrodib is in Phase II to treat specific cancers in the UK, US and EU. Thank you patients, clinicians, clin ops team! pic.twitter.com/kHwD7bDV2Z
Proud to be a recent addition to the ACS BrightEdge investment family, aligned on the mission to defeat cancer. Latest report: brightedgefund.org/system/uploads… pic.twitter.com/3tqUCk4ek5